Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice
Open Access
- 18 September 2006
- journal article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (5) , R150
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease associated with the recognition of self proteins secluded in diarthrodial joints. We have previously established that mice transgenic for the human DR genes associated with RA are susceptible to collagen-induced arthritis (CIA) and we have identified a determinant of type II collagen (CII263–270) that triggers T-cell immune responses in these mice. We have also determined that an analog of CII263–270 would suppress disease in DR1 transgenic mice. Because the immunodominant determinant is the same for both DR1 transgenic and DR4 transgenic mice, we attempted to determine whether the analog peptide that was suppressive in DR1 transgenic mice would also be effective in suppressing CIA in DR4 transgenic mice. We treated DR4 transgenic mice with two analog peptides of CII that contained substitutions in the core of the immunodominant determinant: CII256–276 (F263N, E266D) and CII256–270 (F263N, E266A). Mice were observed for CIA, and T-cell proliferative responses were determined. Either peptide administered at the time of immunization with CII significantly downregulated arthritis. Binding studies demonstrated that replacement of the phenylalanine residue in position 263 of the CII peptide with asparagine significantly decreased the affinity of the peptide for the DR4 molecule. In contrast, replacement of the glutamic acid residue in position 266 with aspartic acid or with alanine had differing results. Aspartic acid reduced the affinity (35-fold) whereas alanine did not. Both peptides were capable of suppressing CIA. With the use of either peptide, CII256–276 (F263N, E266D) or CII256–270 (F263N, E266A), the modulation of CIA was associated with an increase in T-cell secretion of IL-4 together with a decrease in IFN-γ. We have identified two analog peptides that are potent suppressors of CIA in DR4 transgenic mice. These experiments represent the first description of an analog peptide of CII recognized by T cells in the context of HLA-DR4 that can suppress autoimmune arthritis.Keywords
This publication has 25 references indexed in Scilit:
- Functional avidity directs T-cell fate in autoreactive CD4+ T cellsBlood, 2005
- Peptide‐induced suppression of collagen‐induced arthritis in HLA–DR1 transgenic miceArthritis & Rheumatism, 2002
- Adeno-Associated Virus Mediates Long-Term Gene Transfer and Delivery of Chondroprotective IL-4 to Murine SynoviumMolecular Therapy, 2000
- An HLA-DR1 Transgene Confers Susceptibility to Collagen-induced Arthritis Elicited with Human Type II CollagenJournal of Experimental Medicine, 1997
- Human major histocompatibility complex class II-restricted T cell responses in transgenic mice.Journal of Experimental Medicine, 1994
- Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptideNature, 1994
- HLA Genes associated with rheumatoid Arthritis. Identification of susceptibility alleles using specific oligonucleotide probesArthritis & Rheumatism, 1989
- Structural characteristics of an antigen required for its interaction with Ia and recognition by T cellsNature, 1987
- Assessment of the potential pathogenicity of type ii collagen autoantibodies in patients with rheumatoid arthritis. Evidence of restricted IgG3 subclass expression and activation of complement C5 to C5aArthritis & Rheumatism, 1986
- Autoantibody specificities of immune complexes sequestered in articular cartilage of patients with rheumatoid arthritis and osteoarthritisArthritis & Rheumatism, 1985